Publications
12
Citations
6
Est. group size
~3
Recurring co-author estimate
Active years
7
Publishing since 2019
M. Dillhoff's research focuses on the diagnosis, treatment, and outcomes of cancers affecting the liver, pancreas, and bile duct system, including pancreatic ductal adenocarcinoma and liver metastases. This work often examines surgical treatment approaches, treatment barriers, and patient outcomes using large clinical and national databases. Prospective students interested in surgical oncology or health services research in hepato-pancreato-biliary cancers may find this work relevant.
Publication output was minimal and sporadic from 2017-2023 but showed a sharp increase in 2024, suggesting variable and recently growing activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases
HPB · 2024
- Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma
HPB · 2021
- Utilization and Impact of Surgical Treatment of Stage IV Pancreatic Ductal Adenocarcinoma: An Analysis of the National Cancer Database
HPB · 2021
- Association of pre-existing mental illness with all-cause and cancer-specific mortality in medicare beneficiaries with pancreatic cancer
HPB · 2020
- Complex hepato-pancreato-billiary (HPB) caseload during general surgery residency training: Are we adequately training the next generation?
HPB · 2019
- HPB×10
- Endoscopy International Open×1
- Annals of Oncology×1
- J. Madison Hyer
Medicine · The Ohio State University
- Selamawit Woldesenbet
Medicine · The Ohio State University
- Jordan M. Cloyd
Medicine · The Ohio State University
- Matthew J. Weiss
Medicine · The Ohio State University
- Aslam Ejaz
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile